Brief: Medesis Pharma Announces First Inclusions Of Patients In Alzheimer's Disease Phase II Clinical Trial

Medesis Pharma SA

13/06/2022 07:22

June 13 (Reuters) - Medesis Pharma SA  ALMDP.PA :
    * ANNOUNCES THE FIRST INCLUSIONS OF PATIENTS IN THE PHASE II
CLINICAL TRIAL OF ITS NANOLITHIUM PROGRAM FOR THE TREATMENT OF
ALZHEIMER'S DISEASE
    * IS CONDUCTING DEVELOPMENTS FOR THE TREATMENT OF SEVERE
FORMS OF
COVID-19, IN CLINICAL PHASE II IN BRAZIL

Source text for Eikon:  ID:nNDL1sTn53 
Further company coverage:  ALMDP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))